about
Vaccines for Pseudomonas aeruginosa: a long and winding roadInfectious diseases: annual review of significant publications.Support systems for the patient with cancer: future prospects.Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine.Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections.Nosocomial pneumonia in patients in intensive care units.New developments in the treatment of gram-negative bacteremia.Effect of cyclophosphamide on the immune response to Pseudomonas aeruginosa in mice.Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infectionProtective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosaFunctional role of antibody against "core" glycolipid of Enterobacteriaceae.Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06Neutrophil function in gram-negative rod bacteremia. The interaction between phagocytic cells, infecting organisms, and humoral factorsPseudomonas aeruginosa: the potential to immunise against infection.Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice.Polysaccharide of the slime glycolipoprotein of Pseudomonas aeruginosa.Pseudomonas aeruginosa infection in cancer patients.Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa.Preparation and characterization of a nontoxic polysaccharide-protein conjugate that induces active immunity and passively protective antibody against Pseudomonas aeruginosa immunotype 1 in miceRole of lipopolysaccharide in virulence of Pseudomonas aeruginosaRecent developments for Pseudomonas vaccines.Type-specific indirect hemagglutinating antibody in patients with Pseudomonas aeruginosa InfectionLung defenses against Pseudomonas aeruginosa in C5-deficient mice with different genetic backgrounds.Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model.Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.Evaluation of type-specific and non-type-specific pseudomonas vaccine for treatment of pseudomonas sepsis during granulocytopenia.Pulmonary immunity to Pseudomonas aeruginosa.Immunoblot analysis of serological response to Pseudomonas aeruginosa septicaemia in man.Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function.Pseudomonas aeruginosa immunotherapy.Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up.Potential targets for next generation anti-microbial glycoconjugate vaccines.
P2860
Q26852817-C374B683-566E-4658-9092-761ADD628D41Q27486594-0ECEA6D6-6FE7-40D2-BCE0-8A7A821CA647Q33492041-42C32FE2-527F-457C-A072-BDDFE811A325Q34004972-477CC64D-BA85-4ECB-ACD0-571DFE2712C0Q34092742-8EBD498D-2175-4274-A777-F04CB8FE4C0AQ34193009-B3AE15AE-00E6-4E54-B953-759EF5B0303DQ34193370-3404F69B-E873-462E-BD7A-26D3C0DF6774Q34399708-9A2CC97A-0518-4F21-A7F1-3E9C55EF7274Q34455539-EA9D3112-243F-4F67-8700-894D2960BF89Q34463518-EAB7F266-3412-480F-9B8E-08047B324417Q34482763-742CB3F0-DCE1-444A-9B52-337DDD1A6C20Q34535624-9CB8B105-C466-4253-9A3B-23DD8E66694DQ35575338-80CCC202-4C66-4246-9DE2-CD11FCABFAD0Q35775764-13101A72-E8B9-4E99-9F05-00C763A17B01Q35902720-34882659-8E0B-4521-842B-64A5BED646B4Q36194089-B3863839-C01E-43CE-B5EA-3EA87745081EQ36345672-C14E6D8D-9A96-475D-8A31-001622137E94Q36427336-20296FBC-8425-4106-82D6-36B433D6C5C9Q36756527-E675435A-F7AB-4D26-85EA-76D82C6CAAFFQ37035837-986A1521-1D3A-4C3C-AB68-FBBFF8B6B550Q37075805-F20F0733-8CA4-4165-8767-712297E9D710Q37077739-7A368AFE-A3E0-4CB3-9F71-80AE4CC35AA9Q37082940-9487D489-ED69-43E2-AB2B-DA95B48D64FBQ37937369-3168018D-6FE0-43D8-B610-CC840567D266Q39639978-EBACE11A-50A4-493B-A2CD-15FEFD884598Q40165352-D6D6BB7A-4531-4F93-9844-2B6FC5EE6DE7Q40184503-A3CFB5C6-E460-4440-BAE9-1A47A971AADCQ40684695-68F3BBD0-8828-4DF2-8EF2-4E433E24746AQ40905593-BD57B3B9-2726-40C3-8200-BB8A36A8A492Q40966543-DFA8DCAE-C559-4798-BCDE-F6AA49CF3B9DQ42840176-61F025AF-9AF2-4D95-94DC-8D26667325C2Q44472190-5462EA0F-B30B-4051-94F4-0E67ECB46AC2Q45948772-29C67F8E-A86E-4845-BECB-1E20E5585F3EQ52714014-833DF818-7223-4A95-882C-EBF1500728F3Q53701548-4EDA8806-0DDD-464E-9417-286741F6D940
P2860
description
1973 nî lūn-bûn
@nan
1973年の論文
@ja
1973年学术文章
@wuu
1973年学术文章
@zh
1973年学术文章
@zh-cn
1973年学术文章
@zh-hans
1973年学术文章
@zh-my
1973年学术文章
@zh-sg
1973年學術文章
@yue
1973年學術文章
@zh-hant
name
Pseudomonas aeruginosa vaccine in cancer patients.
@en
Pseudomonas aeruginosa vaccine in cancer patients.
@nl
type
label
Pseudomonas aeruginosa vaccine in cancer patients.
@en
Pseudomonas aeruginosa vaccine in cancer patients.
@nl
prefLabel
Pseudomonas aeruginosa vaccine in cancer patients.
@en
Pseudomonas aeruginosa vaccine in cancer patients.
@nl
P2093
P1476
Pseudomonas aeruginosa vaccine in cancer patients.
@en
P2093
P304
P356
10.7326/0003-4819-79-4-518
P407
P577
1973-10-01T00:00:00Z